Humana lifts annual profit forecast as medical costs ease

Humana raised its full-year adjusted profit forecast to at least $9.50 per share from at least $9, above analysts’ average 2026 estimate of $9.15, after quarterly medical costs came in lower than expected. Its medical cost ratio was 93.7% versus the 94.39% analyst estimate, and shares rose 3.2% in morning trading. Humana said its 2027 plan design and stronger Medicare Advantage star ratings position it to target a pre-tax margin of at least 3% in 2028; its CenterWell unit’s cost ratio rose to 95.9%, mainly due to costs among a specific patient group in one geography.

Analysis

The upside is not just a lower near-term cost ratio: Humana may gain share while competitors retrench, then convert 2027 pricing actions and 2028 Star-related payments into a margin recovery. But enrollment growth is only valuable if repricing preserves member economics; aggressive benefit or price choices could attract less profitable members and erode the expected margin gain. The 2028 rating benefit is also partly earmarked for investment, so gross bonus upside should not be treated as equivalent to recurring EPS growth.

Near term, the raised floor and cost outperformance support sentiment, but the 3.2% morning move raises the bar for incremental buyers. Over 1–3 months, watch medical-cost trend commentary, enrollment quality, and the 2027 plan bids—not enrollment alone. Over 6–18 months, the thesis depends on improved margins materializing without sacrificing retention or service quality. The CenterWell cost increase appears geographically concentrated per management; it is a monitor, not yet evidence of a broad deterioration, but persistence would weaken the integrated-care argument.

Contrarian risk: investors may be extrapolating one favorable quarter and ratings tailwind into a smooth recovery. Star ratings and government payment mechanics remain exposed to future performance and policy changes, while medical utilization can reverse. Verify final ratings, bid economics, and whether cost ratios improve as membership scales before underwriting the full 2028 benefit.

Key Decisions for Investors

• Favor a staged long in HUM rather than chasing the earnings-day gap: add on a pullback or after confirmation in the next cost-trend update. The payoff is a multi-year margin-recovery path; the main downside is renewed medical-cost pressure or growth that requires uneconomic pricing.
• Treat HUM as a relative share-gain candidate versus managed-care peers that are retreating from Medicare Advantage, but avoid a broad sector short without evidence that their exits translate into durable HUM pricing power.
• Track quarterly insurance medical cost ratio, 2027 bid/benefit economics, member retention and risk mix, and CenterWell cost trends. Reassess if the cost ratio rises materially from the reported quarter or management cuts the 2026 profit floor; these would challenge the near-term execution case.
• Do not capitalize the full 2028 Star-related benefit as recurring earnings. Confirm the final ratings and the portion directed to investment; adverse rating changes, CMS payment-rule changes, or reinvestment that delays margin conversion would reduce the expected upside.